Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%

被引：0
|
作者：
Irene Fernández-Ruiz
机构：
[1] Nature Reviews Cardiology,
来源：
Nature Reviews Cardiology | 2023年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In a diverse population of patients with heart failure with mildly reduced or preserved ejection fraction stabilized after a recent worsening heart failure event, treatment with sacubitril–valsartan induces greater reductions in plasma NT-proBNP levels and is associated with clinical benefit compared with valsartan alone, despite a higher rate of symptomatic hypotension.
引用
收藏
页码：515 / 515
相关论文
共 50 条
  • [31] Making the case for sacubitril/valsartan in patients with heart failure with a preserved ejection fraction
    Tai, Andrew
    Ambrosy, Andrew P.
    Fudim, Marat
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E5 - E6
  • [32] Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
    Liu, Rex C.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2018, 18 (06) : 473 - 482
  • [33] Sacubitril/Valsartan in heart failure with preserved ejection fraction in women and lower-range preserved ejection fraction
    Dachs, T.
    Nagele, F.
    Rettl, R.
    Dalos, D.
    Duca, F.
    Binder-Rodriguez, C.
    Camuz-Ligios, L.
    Dusik, F.
    Seirer, B.
    Hengstenberg, C.
    Bonderman, D.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S206 - S207
  • [34] Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan
    Diez-Villanueva, Pablo
    Vicent, Lourdes
    de la Cuerda, Francisco
    Esteban-Fernandez, Alberto
    Gomez-Bueno, Manuel
    de Juan-Baguda, Javier
    Manuel Iniesta, Angel
    Ayesta, Ana
    Rojas-Gonzalez, Antonio
    Bover-Freire, Ramon
    Iglesias, Diego
    Garcia-Aguado, Marcos
    Angel Perea-Egido, Jesus
    Salamanca, Jorge
    Martinez-Selles, Manuel
    CARDIOLOGY, 2020, 145 (05) : 275 - 282
  • [35] Prior Heart Failure Hospitalization, Clinical Outcomes, and Effect of Sacubitril/Valsartan Compared With Valsartan in Heart Failure With Preserved Ejection Fraction
    Vaduganathan, Muthiah
    Claggett, Brian
    Anker, Stefan D.
    Perrone, Sergio V., Sr.
    Janssens, Stefan P.
    Milicic, Davor
    Arango, Juan L.
    Packer, Milton
    McMurray, John J.
    Solomon, Scott
    CIRCULATION, 2019, 140 (25) : E995 - E996
  • [36] Early Sacubitril/Valsartan-driven Benefit on Exercise Capacity in Heart Failure With Reduced Ejection Fraction: A Pilot Study
    Palau, Patricia
    Mollar, Anna
    Dominguez, Eloy
    Sanchis, Juan
    Bayes-Genis, Antoni
    Nunez, Julio
    REVISTA ESPANOLA DE CARDIOLOGIA, 2019, 72 (02): : 167 - 169
  • [37] Impact of sacubitril/valsartan treatment on depression and anxiety in heart failure with reduced ejection fraction
    Dereli, Seckin
    Kilincel, Oguzhan
    Cerik, Idris Bugra
    Kaya, Ahmet
    ACTA CARDIOLOGICA, 2020, 75 (08) : 774 - 782
  • [38] The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
    Gronda, Edoardo
    Vanoli, Emilio
    Iacoviello, Massimo
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0L) : L77 - L81
  • [39] Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry
    Maggioni, Aldo P.
    Clark, Andrew L.
    Barrios, Vivencio
    Damy, Thibaud
    Drozdz, Jaroslaw
    Fonseca, Candida
    Lund, Lars H.
    Kalus, Stefanie
    Ferber, Philippe C.
    Hussain, Rizwan, I
    Koch, Cornelia
    Zeymer, Uwe
    ESC HEART FAILURE, 2022, 9 (06): : 4209 - 4218
  • [40] Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction
    Jhund, Pardeep S.
    Alice, M.
    Pfeffer, Marc A.
    Zannad, Faiez
    Lefkowitz, Martin P.
    Shi, Victor
    Vardeny, Orly
    Solomon, Scott
    McMurray, John J.
    CIRCULATION, 2020, 142
12345